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AbstrAct
The aim of this study was to determine the effects 
of glutathione-S-transferase-fused recombinant 
biglycan (GST-BGN) on craniofacial bone regen-
eration. We recently demonstrated a positive effect 
of tissue-derived BGN on bone morphogenetic 
protein 2 (BMP-2) function, which is exerted 
likely via the BGN core protein. Here, we investi-
gated the effects of GST-BGN lacking any post-
translational modifications on BMP-2 function 
in vitro and in vivo. In the C2C12 cell culture system, 
BMP-2-induced Smad 1/5/8 phosphorylation and 
alkaline phosphatase activity were both enhanced 
by the addition of GST-BGN. For the in vivo 
effect, we employed a Sprague-Dawley rat man-
dible defect model utilizing 1 µg (optimal) or 
0.1 µg (suboptimal) of BMP-2 combined with 0, 2, 
4, or 8 µg of GST-BGN. At 2 weeks post-surgery, 
newly formed bone was evaluated by microcom-
puted tomography and histologic analyses. The 
results revealed that the greatest amounts of bone 
within the defect were formed in the groups of 
suboptimal BMP-2 combined with 4 or 8 µg of 
GST-BGN. Also, bone was well organized versus 
that formed by the optimal dose of BMP. These 
results indicate that recombinant BGN is an effi-
cient substrate to promote low-dose BMP-induced 
osteogenesis.
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bone defects of congenital and acquired origins are a major health concern to our society, directly affecting the quality and length of life. To regener-
ate bone, an approach of tissue engineering has been developed consisting of 
a biocompatible scaffold, osteogenic growth factors such as bone morpho-
genetic proteins (BMPs), and stem cells. Yet, the clinical use of BMPs faces 
challenges such as high cost because of the high quantities of BMP required, 
the difficulties to retain BMP in situ, and a robust post-operative inflammatory 
response (Selvig et al., 2002; Smucker et al., 2006; Dickerman et al., 2007).
Biglycan (BGN), a member of class I molecules in the small leucine-rich 
proteoglycan family, is one of the major noncollagenous proteins in mineral-
ized tissues (Fisher et al., 1983). It may function as nucleator for mineral 
deposition in an in vitro system (Boskey et al., 1997) and/or modulator of 
osteoblast and chondroblast activities (Bianco et al., 1990). It also has been 
shown that BGN is a positive modulator of BMP function and promotes 
osteoblast differentiation and mineralization (Chen et al., 2004; Parisuthiman 
et al., 2005). More recently, using tissue-derived BGN, we demonstrated that 
this function is likely exerted through the core protein and that the glycosami-
noglycan (GAG) rather functions as a suppressor (Miguez et al., 2011).
Thus, to explore the potential utility of recombinant BGN for BMP-2-induced 
osteogenesis, we investigated the effect of glutathione-S-transferase-fused BGN 
(GST-BGN) devoid of the posttranslational modifications including GAGs and 
N-glycosylation. Our study characterizes the effects of GST-BGN on BMP sig-
naling and functions by the C2C12 cell assay system and then tests the effect of 
GST-BGN on BMP-2-induced early osteogenesis in a rat mandible defect model. 
The hypothesis tested was that GST-BGN is a potent BMP-2 function promoter 
in vitro and in vivo, leading to predictable bone regeneration.
MAtErIAls & MEtHODs
cell culture
C2C12 cells were cultured as previously described (Mochida et al., 2006). 
Briefly, cells were grown in DMEM (Invitrogen, Carlsbad, CA, USA) with high 
glucose (4.5 g/L) containing 15% FBS (Invitrogen) and supplemented with 100 
U/mL of penicillin G sodium and 100 µg/mL of streptomycin sulfate.
Generation of recombinant bGn and Verification of  
Effect on bMP-2 Function
Recombinant BGN fused with GST tag was generated in an Escherichia coli 
system and purified as previously reported (Mochida et al., 2006). The purity 
of GST-BGN was assessed by 4% to 12% SDS-PAGE stained with CBB and 
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Western blot (WB) with anti-GST antibody (Sigma-Aldrich, St 
Louis, MO, USA). The effect of GST-BGN on rBMP-2 function 
(R&D, Minneapolis, MN) was confirmed by alkaline phospha-
tase (ALP) activity as described elsewhere (Kaku et al., 2007). 
Briefly, after 4 days of culture, cell/matrix was lysed with Tris 
buffer saline containing 0.1% Triton X. ALP activity was mea-
sured with ALP yellow (pNPP; p-nitrophenylphosphate) Liquid 
Substrate System for ELISA (Sigma, St. Louis, MO, USA) 
according to the manufacturer’s protocol. The pNP production 
was measured by absorbance at 405 nm via a 96-well plate 
reader. The protein concentration was determined by a DC 
Protein Assay kit (Bio-Rad, Hercules, CA, USA) and ALP activ-
ity calculated as mol of pNP/min/total protein. A one-way 
analysis of variance was conducted for the variable “treatment” 
at 95% confidence interval (n = 3). The dose effect of GST-BGN 
on BMP-2 signaling was evaluated by adding 2, 4, or 8 µg of 
GST-BGN (based on previous pilot experiments showing no 
effect of BGN at higher concentrations than 8 µg) combined 
with 150 ng per 2 mL of BMP-2 to C2C12 cells, followed by the 
measurement of phosphorylation of Smad 1/5/8. Both experi-
ments were done at least in triplicates.
smad 1/5/8, β-catenin, and ErK 1/2 Phosphorylation
The effects of GST-BGN on Smad and non-Smad BMP-2 sig-
naling pathways were assessed by the phosphorylation of 
Smad1/5/8, β-catenin, and ERK 1/2 in C2C12 cells. Briefly, 
cells were treated with 4 µg of GST-BGN and 150 ng of BMP-2 
for 1 hr and extracted with RIPA buffer. The extracts were then 
applied to 4% to 12% SDS-PAGE followed by WB analyses 
with anti-phospho (p)–Smad 1/5/8, anti-p-β-catenin antibody, or 
anti-p-ERK 1/2 (Cell Signaling, Danvers, MA, USA). Levels 
were normalized to β-actin and β-catenin (cell signaling).
Animal surgery
The surgical procedures were performed as previously described 
(Zellin and Linde, 1997; Miguez et al., 2011). Briefly, 5-mm 
critical-sized defects were generated in mandibles of Sprague-
Dawley male rats via a trephine bur. A collagen scaffold loaded 
with or without proteins was placed within the defect, and bone 
regeneration was evaluated at 2 wk postsurgery. Animal experi-
ments were approved by the Institutional Animal Care and Use 
Committee (ID 09-237.0) at the University of North Carolina at 
Chapel Hill and conform to the ARRIVE guidelines. According 
to Arosarena and Collins (2005), 0.1 µg of BMP-2 is considered 
a “suboptimal” dose of BMP in this model because defects 
exhibit minimal osteogenesis, whereas 1 µg is an “optimal” dose 
to promote accelerated and increased bone regeneration of the 
mandible. Thus, the suboptimal dose of BMP (subBMP) was 
used to evaluate the effect of GST-BGN on BMP-induced bone 
formation. The optimal dose of BMP (optBMP) was used for 
comparison of the amount and organic matrix quality of bone 
formed to those of subBMP with and without BGN. Control 
groups included (1) unfilled defect, (2) collagen scaffold alone 
(Nitta Gelatin Inc, Osaka, Japan), (3) collagen scaffold filled 
with 4 µg of GST-BGN, and (4) collagen scaffold filled with 
4 µg of GST protein alone (i.e., a total of 4 control groups without 
addition of subBMP). Treatment groups received the scaffold 
loaded with (5) subBMP alone or combined with (6) 2 µg of 
GST-BGN, (7) 4 µg of GST-BGN, or (8) 8 µg of GST-BGN and 
(9) optBMP (i.e., a total of 5 treatment groups). Rats were 
euthanized as described (Miguez et al., 2011). Three animals per 
group were implanted for 2 wk, as the optimal dose of BMP-2 
has been shown to promote closure of such mandible defect 
around this time point (Zellin and Linde, 1997).
Microcomputed tomography
The mandibles were fixed in 10% formalin and subjected to 
microcomputed tomography (µCT) analysis via the Scanco 
Medical µCT (Skyscan, Belgium) as previously described 
(Miguez et al., 2011). Bone volume (BV) was determined as 
BV/total area of the newly formed bone (NFB).
Histologic Analyses
Mandibles were demineralized with 0.5 M EDTA, pH 7.4, for 8 wk, 
dehydrated, and embedded in paraffin. Sections (6 µm) obtained 
from the mid–cross section of the mandible defects were stained by 
Masson’s trichrome for histomorphometry or by picrosirius red 
(PSR) to evaluate collagen organization and maturation (Junqueira 
et al., 1979). Osteoclastic activity was analyzed by tartrate-resistant 
acid phosphatase (TRAP) (Yan et al., 2007).
rEsults
Effect of Gst-bGn on bMP-2 signaling  
and Function In Vitro
Figure 1A shows SDS-PAGE stained with CBB for the newly 
generated GST-BGN and GST, revealing the single bands at the 
expected migration positions at ~70 kDa (45 kDa BGN core + 
~26 kDa GST) and ~26 kDa, respectively. WB analysis con-
firmed that both were immunopositive against anti-GST anti-
body (not shown). The statistically significant positive effect of 
GST-BGN on BMP-2-induced ALP activity was observed (lane 
6) compared to BMP-2 alone (lane 4) or BMP-2 + GST (lane 5) 
(Figure 1B), which is consistent with a previous report (Mochida 
et al., 2006). The Smad 1/5/8 phosphorylation (Figure 1C) was 
induced with BMP-2 (lanes 1, 2) and enhanced with the addition 
of 2 µg of GST-BGN (lane 3). Phosphorylation was further 
increased with 4 µg of GST-BGN (lane 4) and stayed at a similar 
level with 8 µg (lane 5).
Figure 1D shows the comparison of Smad and non-Smad 
signaling in C2C12 cells induced by BMP-2 with and without 
4 µg of GST-BGN. Smad 1/5/8 phosphorylation was enhanced 
by GST-BGN in BMP-2-treated C2C12 cells (upper panel); 
β-catenin phosphorylation did not change with BMP-2 in the 
presence or absence of GST-BGN (middle panel) when normal-
ized to total β-catenin. ERK 1/2 phosphorylation was reduced 
with BMP-2 (lane 2), and the addition of GST-BGN (lane 3) had 
no apparent effect. In all these in vitro experiments, GST-BGN 
never exerted any effect by itself at any dose tested, and this was 
observed in repeated experiments with the same GST-BGN or 
with different batches of this bacteria-generated protein.
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tomographic bV of the nFb in the rat Mandibles
Figure 2 shows the representative 3-dimensional (upper panel) 
and 2-dimensional (middle panel) µCT images and BV (lower 
panel). The BV values of control groups—
that is, unfilled, scaffold alone, scaffold + 
GST-BGN, scaffold + GST (not shown)—
were not statistically significantly differ-
ent from that of subBMP (lane 1). 
Compared with these groups, the amounts 
of NFB were significantly higher in the 
optBMP group (lane 2). However, the 
bone induced by optBMP appeared to be 
mainly ectopic (see its 2-dimensional 
image in the middle panel), and less than 
80% of the defect area was filled with 
NFB (defect area identified by upper and 
lower edges of native bone). Addition of 2 
µg of GST-BGN to subBMP-2 (lane 3) 
did not significantly enhance bone forma-
tion compared to that of subBMP-2 alone. 
However, when subBMP was combined 
with 4 or 8 µg of GST-BGN, a significant 
increase in bone formation was observed 
(lanes 4 and 5, respectively), and the 
means were similar to optBMP (Wilcoxon 
rank sum, p > .05).
BV was calculated by the µCT soft-
ware CTan Analyzer (Skyscan, Kontich, 
Belgium).
Histologic Evaluation
In control groups, there was minimal 
NFB at the edge of the defect; thus, not 
all the histologic images are shown. In 
Figure 2, for ease of identification, the 
edge of the NFB is delineated by a dotted 
yellow line and the native bone by a 
solid line. The subBMP group showed a 
small amount of NFB (Figure 2B) 
compared to the scaffold-only group 
(Figure 2A), while the optBMP group 
showed a much greater amount of 
NFB (Figure 2C). Figure 2D, E, and F 
show the images obtained from the 
subBMP groups combined with 2, 4, or 8 
µg of GST-BGN, respectively. While 
NFB/total area percentage did not change 
with the addition of 2 µg of GST-BGN 
to subBMP (15.5 ± 2) (Figure 2D) 
compared to that of subBMP alone 
(8.3 ± 4.2), it increased with 4 µg 
(Figure 2E) and 8 µg of GST-BGN 
(Figure 2F).
PSR staining shown in Figure 3A 
(4×) and B (40×) demonstrates the col-
lagen matrices of the NFB in the subBMP 
group are well organized and mature as 
indicated by the intense red staining of 
the collagen fibers. The NFB of the optBMP group showed light 
yellow to red color with patches of green color, indicating that 
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Figure 1. (A) SDS-PAGE analysis of glutathione-S-transferase-fused biglycan (GST-BGN) and 
GST protein. Molecular weight markers are shown at the very left lane. By SDS-PAGE stained 
with Coomassie Brilliant Blue, GST-BGN migrates at ~70 kDA (lane 1) and GST at about 
26 kDA (lane 2). (b) Alkaline phosphatase (ALP) activity in C2C12 cells (n = 3). Lane 1, no 
treatment; lane 2, GST alone; lane 3, GST-BGN; lane 4, BMP-2 (150 ng); lane 5, BMP-2 + 
GST; lane 6, BMP-2 + GST-BGN. Note that GST-BGN significantly increased BMP-2-induced 
ALP activity in C2C12. (c) Dose effect of GST-BGN on BMP-2 signaling evaluated by 
Smad1/5/8 phosphorylation (n = 3). One representative membrane is shown. Upper panel, 
Western blot analysis; lower panel, Smad1/5/8 phosphorylation normalized to β-actin based 
on the Western blot analysis (densitometry by Scion Image Software, Scion Corporation). Lane 
1, no treatment; lane 2, BMP-2; lane 3, BMP-2 + 2 µg GST-BGN; lane 4, BMP-2 + 4 µg of 
GST-BGN; lane 5, BMP-2 + 8 µg of GST-BGN. Note that 2 µg of GST-BGN increased 
phosphorylation of Smad 1/5/8 (lane 3), as did 4 µg (lane 4), yet 8 µg maintained its level 
(lane 5). (D) Signaling pathways upon BMP-2 and BMP-2 + GST-BGN treatments. Note that 
GST-BGN enhanced BMP-2-induced Smad phosphorylation (upper panel, lane 3). No 
increase in p-β-catenin is seen with any of the treatments (middle panel) after normalization to 
β-catenin. Lower panel shows that BMP-2 reduced p-Erk 1/2 (lane 2), and lane 3 indicates 
that addition of GST-BGN did not change the effect.
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3C); upon higher magnification (Figure 3D), the coloration was 
more faint possibly, indicating a thinner collagen matrix. The 
subBMP + 4 µg and subBMP + 8 µg (Figure 3E) groups 
revealed more red, dense, and thick collagen fibers than those of 
optBMP alone (Figure 3C), as represented by stronger red sig-
naling, although there was some green and yellow scattered 
patches (Dayan et al., 1989). Thus, the use of GST-BGN did not 
compromise the collagen matrix organization/quality as the 
optBMP group did.
TRAP-positive staining was observed only in the optBMP 
group (Figure 4A). In these sections, the TRAP-positive cells 
were found mostly at the surface of the NFB (Figure 4A). Figure 
4B shows a representative image of subBMP + 4 µg GST-BGN 
showing no TRAP-positive cells. Quantification is shown in 
Figure 4C.
DIscussIOn
Recently, we reported that the positive effect of tissue-derived 
BGN on BMP-2 function was likely exerted through its core 
protein (Miguez et al., 2011). In the current study, we tested the 
utility of recombinant GST-BGN devoid of posttranslational 
modifications, including GAGs and N-glycosylation (Neame 
et al., 1989). In the cell culture system, the positive effect was 
observed as previously reported (Mochida et al., 2006). In the 
current study, the dose effect was examined and seen up to 4 µg 
of GST-BGN for 150 ng of BMP-2. The effect stayed at the 
same level with 8 µg of GST-BGN. Saturation of the ratio of 
GST-BGN to BMP and/or to its receptors may have limited 
further effect of GST-BGN on BMP function. Also, it is possible 


























Figure 2. Microcomputed tomography and histologic analyses of the rat mandibles showing 3-dimensional (upper panel) and 2-dimensional 
(middle panel) views of the mandibles. Lower panel shows the bone volume (BV) quantitated by computed tomography analyzer software. Data 
were expressed as bars (means ± standard deviation) and the statistical differences analyzed by Wilcoxon rank sum test to assess the average 
difference between conditions. Note that optBMP (lane 2) shows a tendency of greater BV but is mainly of ectopic nature. The newly formed bone 
by the subBMP + GST-BGN group is seen primarily within the defect (lanes 4 and 5), and BV is similar to optBMP (lane 2). Right panel shows 
Masson’s trichrome staining of (A) scaffold alone (arrow: induction of newly formed bone [NFB] due to periosteum release), (b) subBMP, (c) 
optBMP, (D) subBMP + 2 µg GST-BGN, (E) subBMP + 4 µg GST-BGN, (F) subBMP + 8 µg of GST-BGN. Yellow solid line denotes native bone and 
yellow dotted line NFB. The total area (TA) of the defect was outlined using Image J (National Institutes of Health, Bethesda, MD, USA).
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with high doses of GST-BGN, it potentially limits the BGN 
effect by interfering with the interaction between BMP-2 and its 
receptors.
Under the conditions used, positive effects were consistently 
seen for the Smad 1/5/8 pathway but were not observed for other 
signaling pathways, such as β-catenin and ERK 1/2, by the addi-
tion of BMP-2 or BMP-2 + GST-BGN. The reports on the effect 
of BMP on these signaling pathways are not consistent. Some 
studies showed that BMP-2 activates Wnt/β-catenin in C2C12, 
C3H10T1/2, and MC3T3-E1 cells (Rawadi et al., 2003; Zhang 
et al., 2009), while others reported the lack of such effect 
(Nakashima et al., 2005). In a recent bone fracture–healing 
model, the callus of BGN-deficient mice reduced gene expres-
sion levels of Wnt-induced secreted protein 1, indicating a role 
of BGN in Wnt signaling (Berendsen et al., 2011). The discrep-
ancy between the current study and those reports could be due 
to the assay conditions, such as timing (1-hr incubation in this 
study), passage effect, and culture conditions, among others. 
There are also conflicting reports for the effect of BMP-2 on 
ERK signaling. Gallea et al. (2001) showed an increase of ERK 
phosphorylation with BMP-2 starting only at 2 hours’ post-
treatment in C2C12 cells, while Ghayor et al. (2009) reported a 
decrease in ERK signaling with BMP-2 treatment in C2C12 cells. 
These are likely due to the differences in the concentrations of 
BMP-2 and the timing of the assay. Kinetic studies of BMP-2 and 
BMP-2 + BGN downstream signaling pathways are warranted to 
identify the mechanisms by which BGN positively modulates the 
BMP-2 induced osteogenesis.
In the in vivo study, the NFB volume in the subBMP + 4 µg 
and subBMP + 8 µg groups was significantly greater than those 
of control groups and similar to that of optBMP (Figure 2, lower 
panel). The optBMP group, however, showed significant amounts 
of ectopic bone formation with limited amounts of bone bridging 
the defect. With excessive amounts of BMP-2, it could have led 
to extravasation of BMP to the surrounding tissues. Possibly, a 
greater amount of collagen per scaffold may help retain such large 
amounts of BMP-2. In addition, edema has been associated with 
large quantities of BMP-2 due to exacerbated inflammatory 
response (Shields et al., 2006; Garrett et al., 2010), which could 
contribute to extravasation of BMP to the surrounding connective 
tissues. Nonetheless, GST-BGN in combination with subBMP 
may provide a more predictable means of bone regeneration than 
optBMP, as the NFB was well confined to the defect boundaries. 
BGN has been shown to bind to collagen (Schonherr et al., 1995) 
and BMPs (Mochida et al., 2006). BGN may sequester BMP-2 to 
the extracellular matrix and thus both increase its potency and 
reduce negative effects such as edema.
Osteoclasts were identified only in the optBMP group. As 




Figure 3. Picrosirius red staining of the newly formed bone areas. 
Polarized images of the NFB were taken from the areas immediately 
adjacent to the edge of the defects. (A) subBMP group showing 
collagen fibers in red color (4×), (b) high magnification of the boxed 
area in A (40×), (c) optBMP group showing collagen fibers in green/
yellow to orange color (4×), (D) high magnification of the boxed area 
in C (40×), (E) the subBMP + 8 µg group showing collagen fibers in 
yellow to red color (4×), and (F) high magnification of the boxed area 




















Figure 4. Tartrate-resistant acid phosphatase (TRAP) staining in the 
defects (40×): (A) optBMP, (b) subBMP + 4 µg, (c) number of 
osteoclast-like cells per mm2. Lane 1, subBMP; lane 2, optBMP; lane 3, 
subBMP group + 2 µg GST-BGN; lane 4, subBMP + 4 µg; lane 5, 
subBMP + 8 µg. Trap-positive cells indicated by arrows were found in 
all rats treated with optBMP dose, while they were not detected in the 
subBMP with and without GST-BGN—thus, no bars shown in 
the figure. The number of osteoclast-like cells were counted as cells 
per mm2 of NFB. Scale bar is 200 µm in A.
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bone resorption pits excavated by osteoclasts and increases key 
enzymes for the degradation of bone matrices (Kaneko et al., 
2000), as supported by the pattern of PSR staining (Figure 3C and 
D). When collagen is resorbed and rapidly laid down, the formation 
of well-aligned mature collagen fibrils could be compromised.
In summary, this study accepted the hypothesis proposed and 
demonstrated the following: First, recombinant BGN devoid of 
posttranslational modifications specifically and predictably 
enhances BMP-2 function in vitro and in vivo; second, the bone 
formed by a low dose of BMP-2 combined with GST-BGN was 
well organized and mature when compared with that formed by 
a low or high dose of BMP-2 alone at 2 wk post-surgery; last, 
Smad pathway is consistently activated by BMP-2 and BGN-
assisted BMP-2 osteogenesis in vitro. The data suggest that by 
utilizing a BMP-2 functional effector such as recombinant 
BGN, smaller quantities of BMP-2 could be used to possibly 
minimize adverse side effects, such as ectopic bone formation 
and robust inflammation (Shields et al., 2006; Lee et al., 2011; 
Zara et al., 2011), and effectively regenerate craniofacial bone.
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